Complete knowledge of the proteolytic steps for producing neurotoxic tau fragments can lead to targeting of selected tau-cleaving proteases to inhibit production of highly toxic tau fragments in therapeutic strategies to alleviate tauopathy disease deficits. This evidence concerns the gene MAPT and tauopathy.